Related Experiment Video
Updated: Jun 17, 2026
09:44
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
Published on: March 3, 2015
High throughput screening of normal and neoplastic tissue samples.
Heidi S Erickson1, Gallya Gannot, Michael A Tangrea
1Pathogenetics Unit, Laboratory of Pathology and Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Combinatorial Chemistry & High Throughput Screening
|December 18, 2009
Summary
Developing high throughput screening for disease biomarkers is crucial for personalized medicine. Current methods analyze many markers in few samples or vice versa; the goal is to analyze thousands of markers across thousands of samples efficiently.
Area of Science:
- Biomarker Discovery
- Personalized Medicine
- High Throughput Screening
Background:
- Reliable disease-specific biomarkers are essential for advancing personalized medicine.
- High throughput screening (HTS) of clinical samples aids in discovering diagnostic, prognostic, and therapeutic targets.
- Current HTS capabilities allow analysis of thousands of markers per sample or one marker across many samples.
Purpose of the Study:
- To review the current state and applications of HTS for tissue specimens.
- To discuss the need for enhanced HTS capabilities for biomarker discovery and validation.
- To explore the rationale, challenges, strategies, and technological developments for improving HTS.
Main Methods:
- Review of current high throughput screening technologies for tissue specimens.
- Discussion of applications in biomarker discovery.
- Analysis of technological advancements and challenges in HTS.
Main Results:
- Current HTS enables analysis of thousands of markers from one sample or one marker from thousands of samples.
- There is a need to analyze thousands of markers from thousands of samples to accelerate biomarker discovery and validation.
- Various strategies and new technologies are being developed to meet this need.
Conclusions:
- Advancing HTS technologies is critical for efficient biomarker discovery and validation.
- Improved HTS capabilities will expedite the realization of personalized medicine.
- Continued development is needed to overcome challenges in analyzing large-scale sample and marker data.
